Skip to main content

Table 1 Characteristics of the study participants

From: Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines

  ANTgroup (N=36) NonANT group (N=33) Control group (N=44)
Sex M/F 19/17 16/17 22/22
Diagnosis ALL (33) ALL (33)  
(No. of pts) AML (3)   
Age at diagnosis, yrs 8 (1–17) 5 (2–10)  
Median (range)    
Time since completion of therapy, yrs Median (range) 11 (5–22) 15 (6–25)  
Age at time of the study, yrs 22 (18–31) 23 (17–31) 23 (20–28)
Median (range)    
Chemotherapy Doxorubicin Cyclophosphamide Vincristine  
  Daunorubicin L-Asparaginase  
  Epirubicin Methotrexate  
   6-Mercaptopurine  
  1. Values are presented as median (range).
  2. ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia.